USPTO grants Vermillion Alzheimer's disease biomarker patent

Vermillion, Inc. (Pink Sheets: VRML), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Biomarkers for Alzheimer's disease" to the Company. The patent claims are directed to biomarker combinations for the diagnosis and management of Alzheimer's disease and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay.

"The granting of our Alzheimer's disease biomarker patent is additional validation of our approach to intellectual property protection. We view the increasing breadth of our patent portfolio as a significant corporate asset," said Gail S. Page, CEO and Chairperson.

Source:

Vermillion, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Researchers discover over 40 new genetic markers for Alzheimer’s disease